Trial Profile
A PRELIMINARY OPEN CLINICAL STUDY, TO ASSESS THE SAFETY AND EFFICACY OF RPh201 APPLIED TOPICALLY FOR THE TREATMENT OF HARD TO HEAL CHRONIC ULCERATED WOUNDS
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 10 Sep 2018
Price :
$35
*
At a glance
- Drugs RPh 201 (Primary)
- Indications Chronic wounds
- Focus Adverse reactions
- Sponsors Regenera Pharma
- 10 Jun 2014 New trial record